Related Experiment Video
Updated: Apr 27, 2026
06:27
Use of a Monocyte Monolayer Assay to Evaluate Fcγ Receptor-mediated Phagocytosis
Published on: January 2, 2017
18.7K
Acceptable mismatching at the class II epitope level: the Canadian experience
1aDepartment of Medicine and Immunology, University of Manitoba bDiagnostic Services of Manitoba, Winnipeg, Manitoba, Canada.
Current Opinion in Organ Transplantation
|July 1, 2014
Summary
Human leukocyte antigen (HLA) epitope mismatch analysis better predicts donor-specific antibody (DSA) development than traditional methods. This approach helps minimize DSA and improve long-term allograft survival.
Area of Science:
- Transplantation immunology
- Immunogenetics
Background:
- Donor-specific antibodies (DSA) are a primary cause of organ transplant rejection and graft loss.
- Traditional methods of assessing antigen compatibility may not fully capture the risk of immune response.
Purpose of the Study:
- To review the evidence on human leukocyte antigen (HLA) epitope mismatch analysis for predicting DSA development and allograft survival.
Main Methods:
- Review of existing literature and studies on HLA epitope mismatch analysis.
- Comparison of epitope mismatch analysis with traditional whole molecule antigen matching.
Main Results:
- HLA epitope mismatch analysis is superior to whole molecule antigen matching in predicting the risk of de-novo DSA development.
- Identification of thresholds for epitope mismatches allows stratification of patients into high- or low-risk categories for de-novo DSA.
- Analysis of epitope specificity in DSA-positive patients aids in understanding the immunogenicity of specific HLA epitopes.
Conclusions:
- Minimizing de-novo DSA development is crucial for preventing graft loss.
- HLA epitope mismatch analysis offers a refined strategy to reduce de-novo DSA and enhance long-term allograft survival.
